Stroke (CVA) or TIA(cSTROKE)NCT07013188
Characterising the Neuromuscular Function of Post Stroke Patients
An observational study of Stroke (CVA) or TIA, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
Strokes are a leading cause of death and disability in developed countries, with significant economic and social impacts. Defined by the WHO, strokes cause rapid and lasting disturbances in cerebral function. Read more about this study
- Who is it for?
- Ages 40 to 85 years
- Conditions the study is for
- Stroke (CVA) or TIA
- What is being tested?
- Neuromuscular function
- How many people
- 16 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jun 2024to 1 May 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Post-stroke survival
Who may be able to join
- • Aged between 40-85 years
- Willing and able to give informed consent for participation in the study
- Had a confirmed stroke within the last 5 years
- Self-reports persisting post-stroke loss of unilateral limb function
Who cannot join
- • Diagnosis of cognitive impairment/dementia
- Current or recent (<2y) malignancy
- Severe respiratory disease (e.g., uncontrolled asthma, COPD, pulmonary hypertension)
- Active cardiovascular disease: Uncontrolled hypertension (BP>160/100mmHg); Recent (<12mo) cardiac event; Heart failure (Class III/IV); Significant arrhythmia; Unstable angina
- Metabolic disease: Untreated hyper/hypoparathyroidism; Cushing's disease
- Significant musculoskeletal disorders (based on clinical opinion)
Show all 9Show fewer
- Dialysis patients
- Recent steroid treatment within 6 months or hormone replacement therapy
- Mobility dependant (wheelchair dependency)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Royal Derby Hospital branch, School of Medicine, University of Nottingham
Derby, Derbyshire, DE22 3DT
Abdulmajeed Altheyab, 07944793209, Abdulmajeed.altheyab@Nottingham.ac.uk
Bethan Phillips, Prof
About this study
Official title: Characterising the Neuromuscular Function of Stroke Patients During Recovery
Strokes are a leading cause of death and disability in developed countries, with significant economic and social impacts. Defined by the WHO, strokes cause rapid and lasting disturbances in cerebral function. In the UK, strokes occur every five minutes, affecting 100,000 people annually and resulting in substantial physical impairments and financial costs. Although stroke-related deaths have decreased due to improved treatments and awareness, strokes remain a major cause of death and disability worldwide, especially in lower-income countries. Strokes typically cause unilateral deficits, leading to significant daily challenges and necessitating tailored rehabilitation strategies such as CIMT, FES, and VR Rehab. As the population ages, innovative neurorehabilitation approaches are essential to enhance functional recovery post-stroke. This pilot study aims to better understand the neuromuscular deficits caused by stroke to inform and improve future rehabilitation interventions, including the potential use of force accuracy training (FAT)
Read the detailed description
In developed countries, strokes are the third most common cause of death and disability. Stroke is defined by the World Health Organization (WHO) as "rapidly developed clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than of vascular origin. In 2013, the American Heart Association added the term "silent pathology" to the definition, which includes silent haemorrhage and infarctions of the brain, spinal cord, and retina. A transient ischemic attack (TIA) is considered a "warning stroke" because although it has similar symptoms to a stroke, the symptoms last for less than 24 hours. Furthermore, approximately 50% of strokes happen within 24 hours of a TIA.
The National Institute for Health and Care Excellence (NICE) estimates that in the UK a stroke occurs once every five minutes, and 100,000 people suffer from strokes annually. Further, over 1.3 million individuals in the UK have survived a stroke, with two-thirds of these survivors leaving the hospital with some physical impairment. There are 32,000 stroke-related fatalities annually in England alone, and stroke results in an annual expenditure in the region of £26-billion across the UK. In the previous 15 years, there has been a 49% decrease in the number of deaths caused by stroke in the UK despite an ageing population and that advancing age is a clear risk factor for stroke. This is likely due to advancements in both clinical treatment pathways and public awareness.
Despite this reduction in deaths, in terms of disability-adjusted life-years lost (DALY's), stroke is still the second-highest leading cause of death and is considered to be the third-leading cause of disability globally. In 2020, one in six cardiovascular disease-related deaths were caused by strokes. Global costs associated with stroke are projected to exceed 721 billion dollars (0.66 % of the global GDP). The burden (in terms of the absolute number of cases) grew dramatically from 1990 to 2019, with the bulk of worldwide stroke burden lying in lower and lower to middle-income countries (86.0% of fatalities and 89.0% of DALY's). This rise may be linked to a 70 % increase in incident of strokes, a 44 % increase in stroke-related mortality, a 102 % increase in general strokes, and a 143 % increase in prevalent strokes. Therefore, stroke is a disease of immense importance to the global population's health, with significant repercussions for individuals, the economy and society. In the past, it was believed that stroke primarily impacted wealthy nations. In contrast, the burden of stroke has fallen dramatically in many developed countries due to the use of evidence-based management techniques.
One hallmark of stroke is its tendency to cause unilateral deficits, affecting one side of the body. This can lead to weakness, paralysis, and sensory disturbances. These deficits pose significant challenges for daily activities and can have profound psychological and social impacts. Addressing these unique features is vital in rehabilitation, where tailored interventions can improve outcomes and quality of life for stroke survivors. Some of the current stroke rehabilitation strategies include Constraint-Induced Movement Therapy (CIMT), Task-Specific Training, Functional Electrical Stimulation (FES), Robot-Assisted Therapy, Virtual Reality (VR) Rehab, and Cognitive Rehabilitation. These approaches all aim to maximize recovery and improve functional outcomes post-stroke.
As the number of stroke survivors grows due to demographic shifts in our ageing societies, novel strategies for neurorehabilitation are required. Neural reorganisation is the most important driver of functional recovery after a stroke. An enhanced knowledge of the mechanisms that enable plasticity and recovery is required for the development of novel, neurobiologically informed techniques to promote functional recovery.
In sum, a better understanding of the neuromuscular deficits caused by stroke, which will be gained from this pilot study, will allow enhanced future design of rehabilitation interventions, and will inform the consideration of force accuracy training (FAT) as a potential intervention to improve the neuromuscular and physical function of stroke patients.
- Conditions
- Stroke (CVA) or TIA
- Being tested
- Neuromuscular function
- Keywords
- Stroke, CVA, TIA, Neuromuscular
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromuscular functionOther
Assessing their neuromuscular abilities using some functional and electromyography assessments
| Study group | Role | What they receive |
|---|---|---|
| Stroke patients | * Aged between 40-85 years
* Willing and able to give informed consent for participation in the study
* Had a confirmed stroke within the last 5 years
* Self-reports persisting post-stroke loss of unilateral limb function Receives: Other: Neuromuscular function |
What is being measured
The primary outcome is the main question the study is designed to answer.
Isometric dynamometry
to determine maximum voluntary contraction (MVC) for upper and lower limb extension and flexion, including handgrip dynamometry (in Newton unit)
Measured: During the single testing session (baseline) for the eligible stroke survivors who had a stroke within the past 5 years
High-Density Surface electromyography (HDsEMG) and intramuscular electromyography (iEMG) of the muscles of the upper (bicep and tricep) and lower limbs (vastus lateralis and tibialis anterior) to determine muscle activation patterns
Intramuscular electromyography (iEMG) and high-density sEMG (HD-sEMG) will be used to determine motor unit structure (size \& number) and function (firing rate, firing complexity, neuromuscular junction transmission reliability). sEMG will also be used to determine muscle activation patterns and the largest compound muscle action potential (M-wave). This will be performed using skin electrodes (HDsEMG) and a small pin-type electrode (iEMG) inserted into the upper and lower limb muscles (measured in µVms).
Measured: During the single testing session (baseline) for the eligible stroke survivors who had a stroke within the past 5 years
Motor control assessments for the upper and lower limbs (i.e., force tracking tasks for knee and elbow extension).
Participants will be requested to follow a force trace line on a monitor during extension and flexion movements. The intensity of this force will be relative to their individual capabilities (measured as CoV of force)
Measured: During the single testing session (baseline) for the eligible stroke survivors who had a stroke within the past 5 years
Balance tests
Using a platform that can assess features such as Centre of Pressure (COP) and sway, participants will be asked to stand on both feet, and then on one foot with their eyes open and closed. Time to failure (i.e., need to place second foot on the floor and/or open eyes) will be recorded. A chair will be located behind participants for this assessment and a researcher will remain within touching distance. Participants will only be requested to complete the aspects of this assessment that they feel comfortable doing (measured in millimeter).
Measured: During the single testing session (baseline) for the eligible stroke survivors who had a stroke within the past 5 years
Secondary outcomes (2)
The Grooved Pegboard Test to assess dexterity
This simply involves participants placing small metal pegs into small holes in a specific order. This assessment is timed (in seconds).
Measured: During the single testing session (baseline) for the eligible stroke survivors who had a stroke within the past 5 years
The Trail Making Test (TMT)
is a timed, neuropsychological test that involves visual scanning and working memory (measured in seconds).
Measured: During the single testing session (baseline) for the eligible stroke survivors who had a stroke within the past 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2025
- Study start1 Jun 2024
- Primary completion1 Oct 2025 (estimated)
- Study completion1 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke (CVA) or TIAStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bethan Phillips, University of Nottingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07013188
- Sponsor's protocol ID
- FMHS 188-0524
- Acronym
- (cSTROKE)
- Status last verified
- Apr 2025
- First submitted
- 27 Sep 2024
- Last updated
- 10 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Access to personal (identifiable) information is limited only to research staff involved in the participation elements of this study, and to audit staff as detailed above.